[1]
|
R. P. Raghavan, D. W. Laight, K. M. Shaw and M. H. Cummings, “Aspirin and Diabetes,” British Journal of Diabetes and Vascular Disease, Vol. 6, No. 2, 2006, pp. 74-82.
|
[2]
|
K. De Fea and R. A. Roth, “Protein Kinase C Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation Requires Serine 612,” Biochemistry, Vol. 36, No. 42, 1997, pp. 12939-12947.
|
[3]
|
C. Schmitz-Peiffer, et al., “Alterations in the Expression and Cellular Localization of Protein Kinase C Isozymes Epsilon and Theta Are Associated with Insulin Resistance in Skeletal Muscle of the High Fat Fed Rat,” Diabetes, Vol. 46, No. 2, 1997, pp. 169-178.
doi:10.2337/diabetes.46.2.169
|
[4]
|
G. S. Hotamisligil, N. S. Shargill and B. M. Spiegelman, “Adipose Expression of Tumor Necrosis Factor: Direct Role in Obesity-Linked Insulin Resistance,” Science, Vol. 259, No. 5091, 1993, pp. 87-91.
doi:10.1126/science.7678183
|
[5]
|
L. Rui, et al., “Insulin/IGF-1 and TNF-Alpha Stimulate Phosphorylation of Irs-1 at Inhibitory Ser307 via Distinct Pathways,” The Journal of Clinical Investigation, Vol. 107, No. 2, 2001, pp. 181-189. doi:10.1172/JCI10934
|
[6]
|
G. I. Shulman, “Cellular Mechanisms of Insulin Resistance,” The Journal of Clinical Investigation, Vol. 106, No. 2, 2000, pp. 171-176.
|
[7]
|
A. Dresner, et al., “Effect of Free Fatty Acids on IRS-1 Associated Phosphatidylinositol 3-Kinase Activity,” The Journal of Clinical Investigation, Vol. 103, No. 2, 1999, pp. 25-29. doi:10.1172/JCI5001
|
[8]
|
M. Yuan, et al., “Reversal of Obesityand Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Iκκβ,” Science, Vol. 293, No. 5535, 2001, pp. 1673-1677.
|
[9]
|
J. Kim, et al., “Prevention of Fat-Induced Insulin Resistance by Salicylate,” The Journal of Clinical Investigation, Vol. 108, No. 3, 2001, pp. 437-446.
|
[10]
|
J. Reid, A. I. MacDougall and M. M. Andrews, “Aspirin and Diabetes Mellitus,” British Medical Journal, Vol. 2, No. 5053, 1957, pp. 1071-1074.
doi:10.1136/bmj.2.5053.1071
|
[11]
|
S. G. Gilgore, “The Influence of Salicylate on Hyperglycemia,” Diabetes, Vol. 9, No. 2, 1960, pp. 392-393.
|
[12]
|
M. Gross and L. Greenberg, “The Salicylates,” Hillhouse Press, New Haven, 1948.
|
[13]
|
W. P. Newman and R. G. Brodows, “Aspirin Causes Tissue Insensitivity to Insulin in Normal Man,” The Journal of Clinical Endocrinology and Metabolism, Vol. 57, No. 6, 1983, pp. 1102-1106.
doi:10.1210/jcem-57-6-1102
|
[14]
|
D. Giugliano, L. Sacca, G. Scognamiglio, B. Ungaro and R. Torella, “Influence of Acetylsalicylic Acid on Glucose Turnover in Normal Man,” Diabetes and Metabolism, Vol. 8, No. 4, 1982, pp. 279-282.
|
[15]
|
P. R. Bratusch-Marrain, H. Vierhapper, M. Komjati and W. K. Waldhausl, “Acetyl-Salicylic Impairs Insulin-Mediated Glucose Utilization and Reduces Insulin Clearance in Healthy and Non-Insulin-Dependent Diabetic Man,” Diabetologia, Vol. 28, No. 9, 1985, pp. 671-676.
doi:10.1007/BF00291974
|
[16]
|
M. Yuan, N. Konstantopoulos, J. Lee, L. Hansen, Z. W. Li, M. Karin and S. E. Shoelson, “Reversal of Obesityand Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of IKKβ,” Science, Vol. 293, No. 5535, 2001, pp. 1673-1677. doi:10.1126/science.1061620
|
[17]
|
R. S. Hundal, K. F. Petersen, A. B. Mayerson, P. S. Randhawa, S. Inzucchi, S. E. Shoelson and G. I. Shulman, “Mechanism by Which High-Dose Aspirin Improves Glucose Metabolism in Type 2 Diabetes,” The Journal of Clinical Investigation, Vol. 109, No. 10, 2002, pp. 1321-1326.
|
[18]
|
A. A. Abdin, A. A. Baalash and H. E. Hamooda, “Effects of Rosiglitazone and Aspirin on Experimental Model of Induced Type 2 Diabetes in Rats: Focus on Insulin Resistance and Inflammatory Markers,” Journal of Diabetes and Its Complications, Vol. 24, No. 3, 2010, pp. 168-178.
doi:10.1016/j.jdiacomp.2009.01.005
|
[19]
|
A. Akbarzadeh, D. Norouzian, M. R. Mehrabi, Sh. Jamshidi, A. Farhangi, A. A. Verdi, S. M. A. Mofidian and B. L. Rad, “Induction of Diabetes by Streptozotiocin in Rats,” Indian Journal Of Clinical Biochemistry, Vol. 22, No. 2, 2007, pp. 60-64. doi:10.1007/BF02913315
|
[20]
|
P. Masiello, C. Broca,R. Gross, M. Roye, M. Manteghetti, D. Hillaire-Buys, M. Novelli and G. Ribes, “Experimental NIDDM: Development of a New Model in Adult Rats Administered Streptozotocin and Nicotinamide,” Diabetes February, Vol. 47, No. 2, 1998, pp. 224-229.
doi:10.2337/diabetes.47.2.224
|
[21]
|
R. T. Williamson and M. D. Lond, “On the Treatment of Glycosuria and Diabetes Mellitus with Sodium Salicylate,” British Medical Journal, Vol. 1, No. 2100, 1901, pp. 760-762. doi:10.1136/bmj.1.2100.760
|
[22]
|
R. S. Hundal, K. F. Petersen, A. B. Mayerson, P. S. Randhawa, S. Inzucchi, S. E. Shoelson and G. I. Shulman, “Mechanism by Which High Dose Aspirin Improves Glucose Metabolism in Type 2 Diabetes,” The Journal of Clinical Investigation, Vol. 109, No. 10, 2002, pp. 1321-1326.
|
[23]
|
M. Gross and L. A.Greenberg, “The Salycilates,” Hillhouse Press, New Haven, 1948.
|
[24]
|
J. Reid, A. I. MacDougall and M. M. Andrews, “Aspirin and Diabetes Mellitus,” British Medical Journal, Vol. 2, No. 5053, 1957, pp. 1071-1074.
doi:10.1136/bmj.2.5053.1071
|
[25]
|
S. G. Gilgore, “The Influence of Salicylate on Hyperglycemia,” Diabetes, Vol. 9, No. 5, 1960, pp. 392-393.
|
[26]
|
H. F. Woods, W. A. Stubbs, G. Johnson and K. G. Alberti, “Inhibition by Salicylate of Gluconeogenesis in the Isolated Perfused Rat Liver,” Clinical and Experimental Pharmacology and Physiology, Vol. 1, No. 6, 1974, pp. 535-540. doi:10.1111/j.1440-1681.1974.tb00574.x
|
[27]
|
J. D. Miller, S. Ganguli, R. Artal and M. A. Sperling, “Indomethacin and Salicylate Decreaseepinephrine-Induced Glycogenolysis,” Metabolism, Vol. 34, No. 2, 1985, pp. 148-153. doi:10.1016/0026-0495(85)90124-6
|
[28]
|
J. C. Pickup, M. B. Mattock, G. D. Chusney and D. Burt, “NIDDM as a Disease of the Innate Immune System: Association of Acute-Phase Reactants and Interleukin-6 with Metabolic Syndrome X,” Diabetologia, Vol. 40, No. 11, 1997, pp. 1286-1292. doi:10.1007/s001250050822
|
[29]
|
K. Park, M. Steffes, D. H. Lee, J. H. Himes and D. R. Jacobs, “Association of Inflammation with Worsening Homa-Insulin Resistance,” Diabetologia, Vol. 52, No. 11, 2009, pp. 2337-2344. doi:10.1007/s00125-009-1486-5
|
[30]
|
J. M. Olefsky and C. K. Glassm, “Macrophages, Inflammation, and Insulin Resistance,” Annual Review of Physiology, Vol. 72, 2010, pp. 219-246.
doi:10.1146/annurev-physiol-021909-135846
|
[31]
|
H. Yang, Y. H. Youm, B. Vandanmagsar, A. Ravussin, J. M. Gimble, F. Greenway, J. M. Stephens, R. L. Mynatt and V. D. Dixitm, “Obesity Increases the Production of Proinflammatory Mediators from Adipose Tissue T Cells and Compromises TCR Repertoire Diversity: Implications for Systemic Inflammation and Insulin Resistance,” The Journal of Immunology, Vol. 185, No. 3, 2010, pp. 1836-1845. doi:10.4049/jimmunol.1000021
|
[32]
|
X. D. Sun, F. Han, J. L. Yi, L. Han and B. Wang, “Effect of Aspirin on the Expression of Hepatocyte NF-κB and Serum TNF-α in Streptozotocin-Induced Type 2 Diabetic Rats,” Journal of Korean Medical Science, Vol. 26, No. 6, 2011, pp. 765-770. doi:10.3346/jkms.2011.26.6.765
|
[33]
|
D. Cai, M. Yuan, D. F. Frantz, P. A. Melendez, L. Hansen, J. Lee and S. E. Shoelson, “Local and Systemic Insulin Resistance Resulting from Hepatic Activation of Ikkβ and NF-κB,” Nature Medicine, Vol. 11, No. 2, 2005, pp. 183-190. doi:10.1038/nm1166
|
[34]
|
M. C. Arkan, A. L. Hevener, F. R. Greten, S. Maeda, Z. W. Li, J. M. Long, A. Wynshaw-Boris, G. Poli, J. Olefsky and M. Karin, “IKKβ Links Inflammation to Obesity-Induced Insulin Resistance,” Nature Medicine, Vol. 11, No. 2, 2005, pp. 191-198. doi:10.1038/nm1185
|
[35]
|
J. Yang, Y. Park, H. Zhang, X. Xu, G. A. Laine, K. C. Dellsperger and C. Zhang, “Feed-Forward Signaling of TNF-α and NF-κB via IKKβ Pathway Contributes to Insulin Resistance and Coronary Arteriolar Dysfunction in Type 2 Diabetic Mice,” American Journal of Physiology Heart and Circulatory Physiology, Vol. 296, No. 6, 2009, pp. H1850-H1858. doi:10.1152/ajpheart.01199.2008
|
[36]
|
C. Watala, J. Golanski, J. Pluta, M. Boncler, M. Rozalski, B. Luzak, A. Kropiwnicka and J. Drzewoski, “Reduced Sensitivity of Plateletsfrom type 2 Diabetic Patients to Acetylsalicylic Acid (Aspirin)-Its Relation to Metabolic Control,” Thrombosis Research, Vol. 113, No. 2, 2004, pp. 101-113. doi:10.1016/j.thromres.2003.12.016
|
[37]
|
S. Fateh-Moghadam, U. Plockinger, N. Cabeza, P. Htun, T. Reuter, S. Ersel, M. Gawaz, R. Dietz and W. Bocksch, “Prevalence of Aspirinresistance in Patients with Type 2 Diabetes,” ActaDiabetologica, Vol. 42, No. 2, 2005, pp. 99-103. doi:10.1007/s00592-005-0186-y
|
[38]
|
W. P. Newman and R. G. Brodows, “Aspirin Causes Tissue Insensitivity to Insulin in Normal Man,” The Journal of Clinical Endocrinology and Metabolism, Vol. 57, No. 6, 1983, pp. 1102-1106. doi:10.1210/jcem-57-6-1102
|
[39]
|
D. Giugliano, L. Sacca, G. Scognamiglio, B. Ungaro and R. Torella, “Influence of Acetylsalicylic Acid on Glucose Turnover in Normalman,” Diabetes and Metabolism, Vol. 8, No. 4, 1982, pp. 279-282.
|
[40]
|
M. G. Netea, C. J. Tack, P. M. Netten, J. A. Lutterman and J. W. M. Van Der Meer, “The Effect of Salicylates on Insulin Sensitivity,” The Journal of Clinical Investigation, Vol. 108, No. 11, 2001, pp. 1723-1724.
doi:10.1172/JCI14455
|
[41]
|
P. M Ridker, N. R. Cook, M. B. M. Lee, M. A. D. Gordon, J. M. Gaziano, J. E. Manson, C. H. Hennekens and J. E. Buring, “A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women,” The New England Journal of Medicine, Vol. 352, 2005, pp. 1293-304. doi:10.1056/NEJMoa050613
|